Almirall är Diamant-sponsor under NCDV, Nordic Congress of Dermatology and Venereology, den 7-9 maj 2025 i Helsingfors
Almirall är Diamont-sponsor på NCDV i Helsingfors 7-9 maj 2025!
Senaste nyheterna
-
-
Almirall firar internationella psoriasisdagen den 29 oktober 2024
Årets kampanj från Almirall under internationella psoriasisdagen heter "Me & My Inner Circle".
-
Almirall’s Ilumetri® (tildrakizumab) demonstrates high rates of skin clearance and sustained wellbeing restoration in Adults with Moderate-to-Severe Plaque Psoriasis to general population levels for up to one year (1)
• Almirall presented the interim Week 52 results of the POSITIVE clinical study at the IFPA Conference 2024, showing the benefits of the effective treatment with Ilumetri (tildrakizumab) in patients with moderate to severe psoriasis achieving improvement of physical symptoms and overall wellbeing
• This first-of-its-kind study underscores the psychosocial burden of psoriasis and its deep im -
Almirall initiates first phase I clinical study of ALM223, an interleukin 2 mutant fusion protein for autoimmune diseases
• The phase I study will evaluate the safety, pharmacokinetics, immunogenicity, and pharmacodynamics of ALM223
• ALM223 has the potential to rebalance the immune system in several autoimmune diseases (1,2)
BARCELONA, Spain. 21st December, 2023 – Almirall S.A. (BME: ALM), a global pharmaceutical company focused on medical dermatology, today announced the initiation of the phase I stud -
Almirall and etherna enter into a multi-target alliance to develop mRNA-based therapies in medical dermatology
• The multi-target research and development partnership will focus on severe skin diseases
• The collaboration leverages etherna’s proprietary mRNA and lipid nanoparticle (LNP) technology with Almirall’s expertise in the dermatology space
• In addition to upfront and technology access payments, etherna is eligible to receive €300 million in development and commercial milestones as well as t -
Almirall får EU-godkännande av EBGLYSS® (lebrikizumab) för behandling av måttlig till svår atopisk dermatit
Lebrikizumab är en monoklonal antikropp som binder till IL-13 med hög affinitet och selektivt hämmar nedströms signalering (1-4). Lebrikizumab har visat tidig klinisk effekt och bibehållen respons i upp till 2 år, både som monoterapi och i kombination med topikala kortikosteroider (5-8). Tyskland är det första landet där lebrikizumab kommer att finnas tillgängligt för förskrivning.
Almirall, et -
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
The collaboration expands Absci’s de novo AI drug creation portfolio into dermatology and accelerates discovery for broader chronic inflammatory diseases
BARCELONA, Spain and VANCOUVER, (WA), USA. November 14th, 2023 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today
Kontakter
-
Christian Bruun-Andersen Presskontakt General Manager, Nordics christian.bruun-andersen@almirall.com (+45) 31 62 83 53
-
External communication team Presskontakt Europe corporate.communication@almirall.com
